Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Clin Drug Investig. 2010;30(11):799-804. doi: 10.2165/11537220-000000000-00000.
Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.
索拉非尼是一种肿瘤细胞增殖和血管生成的多激酶抑制剂，已被证明在治疗转移性肾细胞癌（RCC）方面具有作用。Xp11 易位癌是 RCC 的一种罕见亚型。我们报告了一例转移性 Xp11 易位 RCC 男性患者，他对索拉非尼治疗有反应。开始索拉非尼治疗 6 周后，患者的 CT 扫描显示肾脏肿块和主动脉旁淋巴结的中央坏死增加，以及肺部和胸膜肿块的消退。患者无进展生存期为 12 个月，总生存期为 15 个月。最严重的不良反应为 3 级皮炎和 3 级贫血。本病例首次证明索拉非尼对 Xp11 易位 RCC 具有活性。
